Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · children aged 12 to 18 years
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion showed no clear difference in serious adverse events compared with placebo/no pharmacological treatment (moderate certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion plus nicotine replacement therapy (NRT) showed no clear difference in serious adverse events compared with NRT alone (low certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion plus varenicline showed no clear difference in serious adverse events compared with varenicline alone (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing pancreaticoduodenectomy
1 finding from 1 review
Intervention not reported
Serious adverse events · people undergoing distal pancreatectomy
1 finding from 1 review
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Serious adverse events
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Serious adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (during · children or adults with Types I or II HAE
C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).
1 finding from 1 review
Adverse events (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult patients after liver transplantation.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found